Table 1.
Patient and tumor characteristics
| Patient and treatment characteristics | p-value | ||
|---|---|---|---|
| Age | Median | 65 | 0,36 |
| Range | 44–83 | ||
| KPS | Median | 70 | 0,1 |
| Range | 50–90 | ||
| Sex | Male | 45 | 0,13 |
| Female | 21 | ||
| Weight loss > 5 % | None | 49 | 0,7 |
| Yes | 17 | ||
| Stage | T | T1: 14 | <0,001 |
| T2: 32 | |||
| T3: 11 | |||
| T4:9 | |||
| N | N0: 3 | 0,07 | |
| N1: 7 | |||
| N2: 43 | |||
| N3: 13 | |||
| UICC | II: 4 | x | |
| IIIA: 44 | |||
| IIIB: 18 | |||
| Tumor location | right lung | 36 | 0,8 |
| left lung | 30 | ||
| upper lobe | 48 | 0,44 | |
| middle lobe | 2 | ||
| lower lobe | 16 | ||
| peripheral | 38 | 0,33 | |
| central | 28 | ||
| Histology | SCC | 39 | 0,26 |
| AC | 21 | ||
| NOS | 6 | ||
| Group | I (<2,5 cm) | 12 | x |
| II (2,5–4,5 cm) | 32 | ||
| III (4,5–6 cm) | 13 | ||
| IV (>6 cm) | 9 | ||
| PTV tumor (ml) | Median | 93 | <0,001 |
| Range | 16–528 | ||
| Tumor dose (Gy) | Median | 79,2 | <0,001 |
| Range | 73,8–90 | ||
| Lymph node dose (Gy) | Median | 61 | 0,38 |
| Range | 0–90 | ||
| ENIa (Gy) | Median | 45 | 0,43 |
| Range | 0–63 | ||
The distribution of patient and tumor characteristics over the four dose groups was tested with the Kruskal-Wallis-Test (x = not tested, a = elective nodal irradiation). Significant differences were found – as expected – in group-related parameters (T-stage, N-stage, tumor dose, PTV tumor)